Two-dimensional difference gel electrophoresis urinary proteomic profile in the search of nonimmune chronic allograft dysfunction biomarkers

Transplantation

Volumn 89, Issue 5, 2010, Pages 548-558

  Banon Maneus, Elisenda ^a   Diekmann, Fritz ^a   Carrascal, Montserrat ^b   Quintana, Luis F ^a   Moya Rull, Daniel ^a   Bescós, Monica ^a   Ramírez Bajo, Maria J ^a   Rovira, Jordi ^a   Gutierrez Dalmau, Alex ^a   Solé González, Amanda ^a   Abián, Joaquin ^b   Campistol, Josep M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INST D INVESTIGACIONS B   (Spain)

Author keywords

2DE DIGE; CAD; IFTA; Urinary proteome

Indexed keywords

BIOLOGICAL MARKER; MYCOPHENOLIC ACID; PLASMA PROTEIN; PREDNISONE; PROTEOME; SILVER; TACROLIMUS;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FIBROSING ALVEOLITIS; GENE MAPPING; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEOMICS; RENAL GRAFT DYSFUNCTION; SILVER STAINING; TWO DIMENSIONAL GEL ELECTROPHORESIS; URINALYSIS;

AMINO ACID SEQUENCE; ATROPHY; BIOLOGICAL MARKERS; BIOPSY; DRUG THERAPY, COMBINATION; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; EXTRACELLULAR FLUID; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOELECTRIC FOCUSING; KIDNEY TRANSPLANTATION; KIDNEY TUBULES; PEPTIDES; POSTOPERATIVE COMPLICATIONS; PROTEINURIA; PROTEOME; TRANSPLANTATION, HOMOLOGOUS;

EID: 77949411194     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181c690e3     Document Type: Article

References (52)

1. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605.
2. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004; 4: 1289.
3. Nankivell BJ, Chapman JR. Chronic allograft nephropathy: Current concepts and future directions. Transplantation 2006; 81: 643.
4. Solez K, Colvin RB, Racusen LC, et al. Banff '05 meeting report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ("CAN"). Am J Transplant 2007; 7: 518.
5. Beckingham IJ, Nicholson ML, Bell PR. Analysis of factors associated with complications after renal transplant needle core biopsy. Br J Urol 1994; 73: 13.
6. Huraib S, Goldberg H, Katz A, et al. Percutaneous needle biopsy of the transplanted kidney: Technique and complications. Am J Kidney Dis 1989; 14: 13.
7. Curtis JJ, Julian BA, Sanders CE, et al. Dilemmas in renal transplantation: When the clinical course and histological findings differ. Am J Kidney Dis 1996; 27: 435.
8. Sorof JM, Vartanian RK, Olson JL, et al. Histopathological concordance of paired renal allograft biopsy cores. Effect on the diagnosis and management of acute rejection. Transplantation 1995; 60: 1215.
9. Rush DN, Nickerson P, Jeffery JR, et al. Protocol biopsies in renal transplantation: Research tool or clinically useful? Curr Opin Nephrol Hypertens 1998; 7: 691.
10. Wittke S, Haubitz M, Walden M, et al. Detection of acute tubulointer-stitial rejection by proteomic analysis of urinary samples in renal transplant recipients. Am J Transplant 2005; 5: 2479.
11. González-Buitrago JM, Ferreira L, Lorenzo I. Urinary proteomics. Clin Chim Acta 2007; 375: 49.
12. Iwaki H, Kageyama S, Isono T, et al. Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, gamma-synuclein, and catechol-o-methyltransferase) identified by proteomic analysis. Cancer Sci 2004; 95: 955.
13. Clarke W, Silverman BC, Zhang Z, et al. Characterization of renal al-lograft rejection by urinary proteomic analysis. Ann Surg 2003; 237: 660.
14. Fliser D, Novak J, Thongboonkerd V, et al. Advances in urinary pro-teome analysis and biomarker discovery. J Am Soc Nephrol 2007; 18: 1057.
15. Thongboonkerd V. Proteomics in nephrology: Current status and future directions. Am J Nephrol 2004; 24: 360.
16. Dihazi H, Müller GA. Urinary proteomics: A tool to discover biomar-kers of kidney diseases [review]. Expert Rev Proteomics 2007; 4: 39; erratum 327.
17. Oh J, Pyo JH, Jo EH, et al. Establishment of a near-standard two-dimensional human urine proteomic map. Proteomics 2004; 4: 3485.
18. Thongboonkerd V, McLeish KR, Arthur JM, et al. Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation. Kidney Int 2002; 62: 1461.
19. Yoshida Y, Miyazaki K, Kamiie J, et al. Two-dimensional electro-phoretic profiling of normal human kidney glomerulus proteome and construction ofan extensible markup language (XML)-based database. Proteomics 2005; 5: 1083.
20. Unlü M, Morgan ME, Minden JS. Difference gel electrophoresis: A single gel method for detecting changes in protein extracts. Electro-phoresis 1997; 18: 2071.
21. Alban A, David SO, Bjorkesten L, et al. A novel experimental design for comparative two-dimensional gel analysis: Two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Pro-teomics 2003; 3: 36.
22. ShawJ, Rowlinson R,Nickson J, et al. Evaluation ofsaturation labelling two-dimensional difference gel electrophoresis fluorescent dyes. Pro-teomics 2003; 3: 1181.
23. Wu TL. Two-dimensional difference gel electrophoresis. Methods Mol Biol 2006; 328: 71.
24. Gazzana G, Borlak J. Improved method for proteome mapping of the liver by 2-DE MALDI-TOF MS. J Proteome Res 2007; 6: 3143.
25. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification for renal allograft pathology. Kidney Int 1999; 55: 713.
26. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria\An addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708.
27. Vongwiwatana A, Gourishankar S, Campbell PM, et al. Peritubular capillary changes and C4d deposits are associated with transplant glo-merulopathy but not IgA nephropathy. Am J Transplant 2004; 4: 124.
28. Quero C, Colomé N, Prieto MR, et al. Determination of protein markers in human serum: Analysis of protein expression in toxic oil syndrome studies. Proteomics 2004; 4: 303.
29. Carrascal M, Ovelleiro D, Casas V, et al. Phosphorylation analysis of primary human T lymphocytes using sequential IMAC and titanium oxide enrichment. J Proteome Res 2008; 7: 5167.
30. Edwards JJ, Tollaksen SL, Anderson NG. Proteins of human urine. III. Identification and two-dimensional electrophoretic map positions of some major urinary proteins. Clin Chem 1982; 28(4 Pt 2): 941.
31. Adachi J, Kumar C, Zhang Y, et al. The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol 2006; 7: R80.
32. Candiano G, Musante L, Petretto A, et al. Proteomics of plasma and urine in primary nephrotic syndrome in children. Contrib Nephrol 2008; 160: 17.
33. NiwaT.Biomarker discovery for kidney diseases bymass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 870: 148.
34. Quintana LF, Solé-Gonzalez A, Kalko SG, et al. Urine proteomics to detect biomarkers for chronic allograft dysfunction. J Am Soc Nephrol 2009; 20: 428.
35. Quintana LF, Campistol JM, Alcolea MP, et al. Application of label-free quantitative peptidomics for the identification of urinary biomarkers of kidney chronic allograft dysfunction. Mol Cell Proteomics 2009; 8: 1658.
36. Goligorsky MS, Addabbo F, O'Riordan E. Diagnostic potential of urine pro-teome: A broken mirror of renal diseases. J Am Soc Nephrol 2007; 18: 2233.
37. Zhang X,JinM, Wu H, et al. Biomarkers of lupus nephritis determined by serial urine proteomics. Kidney Int 2008; 74: 799.
38. Ting SM, Toth T, Caskey F. Alpha1-antitrypsin (A1AT) deficiency presenting with IgA nephropathy and nephrotic syndrome: Is renal involvement caused by A1AT deposition? Clin Nephrol 2008; 70: 159.
39. Ngai HH, Sit WH, Jiang PP, et al. Markedly increased urinary prepro-haptoglobin and haptoglobin in passive Heymann nephritis: A differential proteomics approach. J Proteome Res 2007; 6: 3313.
40. Kobori H, Ohashi N, Katsurada A, et al. Urinary angiotensinogen as a potential biomarker of severity of chronic kidney diseases. J Am Soc Hypertens 2008; 2: 349.
41. Jourde-Chiche N, Dou L, Sabatier F, et al. Levels of circulating endo-thelial progenitor cells are related to uremic toxins and vascular injury in hemodialysis patients. J Thromb Haemost 2009; 7: 1576.
42. Oetting WS, Rogers TB, Krick TP, et al. Urinary beta2-microglobulin is associated with acute renal allograft rejection. Am J Kidney Dis 2006; 47: 898.
43. Okubo K, Hayashi K, Wakino S, et al. Role of asymmetrical dimethyl-arginine in renal microvascular endothelial dysfunction in chronic renal failure with hypertension. Hypertens Res 2005; 28: 181.
44. Gokden N, Barlogie B, Liapis H. Morphologic heterogeneity of renal light-chain deposition disease. Ultrastruct Pathol 2008; 32: 17.
45. Madalena L, Facio ML, Angerosa M, et al. Urinary excretion of low molecular weight proteins inpatients with pure monoclonal light chain proteinuria. J Nephrol 2007; 20: 683.
46. Hutchison CA, Harding S, Hewins P, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 1684.
47. Serra AL, Kistler AD, Poster D, et al. Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2009; 24: 3334.
48. Paskhina TS, Platonova LV, Poliantseva LR. [Trypsin inhibitor in the urine of patients with glomerulonephritis]. Vopr Med Khim 1988; 34: 89.
49. Jirka J, Burianova B, Jirka M, et al. Human serum Zn-alpha 2-glycop-rotein in renal disease. Biomedicine 1976; 25: 246.
50. Shibata S, Miura K. Nephritogenic glycoprotein. IX. Plasma Zn-al-pha2-glycoprotein as a second source of nephritogenic glycoprotein in urine. Nephron 1982; 31: 170.
51. Harris DA, Schwartz JH. Characterization of brevin, a serum protein that shortens actin filaments. Proc Natl Acad Sci USA 1981; 78: 6798.
52. Bernfield M, Götte M, Park PW, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999; 68: 729.